Insider · CIK 0001219871
David M Mott
Files at NVAX (NOVAVAX INC), ARDX (ARDELYX, INC.), MRSN (Mersana Therapeutics, Inc.). First filing Nov 14, 2024, latest Jun 18, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ARDX: ARDELYX, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | ARDXbuy ARDELYX, INC. | $726k 200,000 shares | +7% | +12% from low-47% from high | |
| 52Moderate | ARDXbuy ARDELYX, INC. | $737k 200,000 shares | +8% | +15% from low-46% from high | |
| 53Moderate | ARDXbuy ARDELYX, INC. | $329k 100,000 shares | +4% | +3% from low-51% from high | |
| 66Notable | ARDXbuy ARDELYX, INC. | $1.6M 381,377 shares | +19% | 0% from low-40% from high | |
| 40Moderate | ARDXbuy ARDELYX, INC. | $389k 77,729 shares | +4% | +14% from low-26% from high | |
| 62Notable | ARDXbuy ARDELYX, INC. | $993k 199,000 shares | +11% | +9% from low-29% from high | |
| 48Moderate | ARDXbuy ARDELYX, INC. | $997k 213,300 shares | +15% | - | |
| 43Moderate | ARDXbuy ARDELYX, INC. | $997k 215,868 shares | +18% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | NVAX NOVAVAX INC | AGrant or award Stock Option (Right to Buy)derivative | +28,326 | $6.42 | $182k | 28,326 | Jun 24, 2025 |
| Jun 20, 2025 | NVAX NOVAVAX INC | AGrant or award Restricted Stock Unitsderivative | +18,884 | $0.00 | $0 | 18,884 | Jun 24, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +31,163 | $0.00 | $0 | 2,928,034 | Jun 23, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +41,551 | $0.00 | $0 | 2,969,585 | Jun 23, 2025 |
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +54,059 | $0.00 | $0 | 54,059 | Jun 23, 2025 |
| Jun 16, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +200,000 | $3.63 | $726k | 2,896,871 | Jun 18, 2025 |
| Jun 12, 2025 | MRSN Mersana Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
| Jun 12, 2025 | NVAX NOVAVAX INC | MOption exercise Common Stock | +10,420 | $0.00 | $0 | 60,890 | Jun 13, 2025 |
| Jun 12, 2025 | NVAX NOVAVAX INC | MOption exercise Restricted Stock Unitsderivative | -10,420 | $0.00 | $0 | 0 | Jun 13, 2025 |
| Jun 9, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +200,000 | $3.69 | $737k | 2,696,871 | Jun 11, 2025 |
| May 15, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +100,000 | $3.29 | $329k | 2,496,871 | May 19, 2025 |
| May 2, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +381,377 | $4.22 | $1.6M | 2,396,871 | May 5, 2025 |
| Feb 24, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +77,729 | $5.00 | $389k | 2,015,494 | Feb 26, 2025 |
| Jan 21, 2025 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +199,000 | $4.99 | $993k | 1,937,765 | Jan 22, 2025 |
| Dec 26, 2024 | ARDX ARDELYX, INC. | MOption exercise Common Stock | +100,000 | $0.55 | $55k | 1,738,765 | Dec 27, 2024 |
| Dec 26, 2024 | ARDX ARDELYX, INC. | MOption exercise Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 0 | Dec 27, 2024 |
| Dec 19, 2024 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +213,300 | $4.67 | $997k | 1,638,765 | Dec 23, 2024 |
| Nov 13, 2024 | ARDX ARDELYX, INC. | POpen-market purchase Common Stock | +215,868 | $4.62 | $997k | 1,425,465 | Nov 14, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.